Prevnar Family — Revenues:
Pfizer Prevnar Family — Revenues: decreased by 1.1% to $1.69B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.8%, from $1.66B to $1.69B. Over 4 years (FY 2021 to FY 2025), Prevnar Family — Revenues: shows an upward trend with a 5.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in revenue signals strong market demand, successful uptake of new vaccine formulations, or effective expansion into new patient demographics. A decrease may indicate increased competition from rival vaccine manufacturers, loss of patent exclusivity, or shifts in public health procurement policies.
Detailed definition
This metric represents the total gross sales generated by a specific portfolio of pneumococcal conjugate vaccines within...
Peer comparison
Comparable to revenue metrics for specific blockbuster drug franchises or vaccine portfolios at major global pharmaceutical peers, often evaluated based on market share and therapeutic category dominance.
pfe_segment_prevnar_family_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.24B | $1.45B | $1.30B | $1.57B | $1.43B | $1.61B | $1.74B | $1.60B | $1.43B | $1.84B | $1.62B | $1.69B | $1.36B | $1.80B | $1.56B | $1.66B | $1.38B | $1.74B | $1.71B | $1.69B |
| QoQ Change | — | +16.6% | -10.1% | +20.3% | -8.7% | +12.5% | +8.3% | -8.0% | -10.7% | +28.8% | -11.9% | +4.1% | -19.6% | +32.7% | -13.6% | +6.5% | -16.7% | +26.0% | -2.0% | -1.1% |
| YoY Change | — | — | — | — | +15.1% | +11.1% | +33.8% | +2.4% | +0.1% | +14.7% | -6.7% | +5.6% | -5.0% | -2.2% | -4.1% | -1.8% | +1.8% | -3.4% | +9.6% | +1.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's prevnar family — revenues:?
- Pfizer (PFE) reported prevnar family — revenues: of $1.69B in Q1 2026.
- How has Pfizer's prevnar family — revenues: changed year-over-year?
- Pfizer's prevnar family — revenues: increased by 1.8% year-over-year, from $1.66B to $1.69B.
- What is the long-term trend for Pfizer's prevnar family — revenues:?
- Over 4 years (2021 to 2025), Pfizer's prevnar family — revenues: has grown at a 5.3% compound annual growth rate (CAGR), from $5.27B to $6.49B.
- What does prevnar family — revenues: mean?
- The total revenue generated from the sales of a specific brand family of vaccines.